This site is intended for healthcare professionals

Detail videa

22. 1. 2021 | CZE

AGING PSEUDO-PROGRESSION IN PATIENTS ON IMMUNE CHECKPOINT INHIBITOR THERAPY

klinická onkologie, imunoterapie onkologických onemocnění

doc. MUDr. Ing. Lukáš Lambert, Ph.D.

Souhrn

Immunotherapy invokes activation of the immu­ne system, initial enlargement of current lesions and the appearance of new lesions usually within the first weeks from the initiation of the treatment in up to 10 % of patients. Early and precise recognition of pseudo-progression can prevent premature discontinuation of immunotherapy. Several criteria to discern pseudo-progression (unconfirmed progressive disease) from true hy­per-progression (confirmed progressive disea­se) have been described (irRC, iRECIST, imRE­CIST). They are based on early restaging within 4–8 weeks with the evidence of subsequent drop in tumour burden. However, pseudo-progression can last up to 3 months. Some patients may benefit from treatment beyond progression or progression followed by stabilization. Apart from morphological criteria, attempts have been made to recognize pseudo-progression by the means of MR spectroscopy, MR with super-paramagnetic nanoparticles, PET/CT, perfusion imaging.


Prezentace ke stažení

  • doc. MUDr. Ing. Lukáš Lambert, Ph.D. – Lukáš Lambert_Zobrazování pseudoprogrese při léčbě checkpoint inhibitory

Podobné

9. 6. 2022 | CZE

COVID A PSYCHÉ pohledem psychosomatiky

psychiatrie

MUDr. Radin Honzák, CSc.

13. PragueONCO

9. 6. 2022 | CZE

Inhibitory kináz příbuzných...

klinická onkologie

prof. MUDr. Martina Řezáčová, Ph.D.

13. PragueONCO

9. 6. 2022 | CZE

Poškození a reparace DNA různými druhy...

klinická onkologie

doc. RNDr. Martin Falk, Ph.D.

13. PragueONCO

Další videa

Komerce

Partneři projektu